FDA Joint Reviews Would Benefit From Early Collaboration Meetings – Lewin
This article was originally published in The Gray Sheet
Executive Summary
FDA should rely increasingly on early collaboration meetings in the review of combination products, according to the fourth in a series of reports prepared by The Lewin Group health care consultant for AdvaMed